Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continued regorafenib treatment for participants rolling over from prior Bayer regorafenib studies
2023-507084-19-00Phase 2Completed
- Sponsor
- Bayer
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of regorafenib in Non-hematologic malignancy, sponsored by Bayer. Primary endpoint: Number of participants with serious adverse events and protocol-specified adverse events and their severity. Started Mar 2024; status: completed.
02
Drugs
regorafenib
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on 2023-507084-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507084-19-00.